Citations

Clear

174 citation(s) found for "Winham, SJ".

Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers
Mahmoudzadeh, Amir Pasha , Ma, Lin , Jensen, Matthew R. , Wu, Fang , Cummings, Steven R. , Shepherd, John , Brandt, Kathleen R. , Miglioretti, Diana L. , Vachon, Celine M. , Winham, Stacey, Miglioretti, Diana L , Kerlikowske, Karla , Scott, Christopher G. , Winham, Stacey J. , Wu, Fang Fang, Malkov, Serghei , Pankratz, V. Shane , Vachon, Celine M.

Mayo Clinic

Annals of Internal Medicine | April 30, 2018 | Volume: 168 | Issue: 11 | Pages: 757-765

10.7326/m17-3008 | PMID 29710124 Get It

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia
Frank, Ryan D. , Dupont, William D. , Vierkant, Robert A. , Frost, Marlene H., Vachon, Celine M. , Ghosh, Karthik, Carter, Jodi M. , Denison, Lori A., Broderick, Brendan T., Hartmann, Lynn C. , Visscher, Daniel W., Hoskin, Tanya L. , Broderick, Brendan, Radisky, Derek C. , Vierkant, Robert A , Degnim, Amy C. , Winham, Stacey J. , Pankratz, V. Shane , Vachon, Celine M. , Hieken, Tina J. , Carter, Jodi

Mayo Clinic

Journal of Clinical Oncology | April 20, 2018 | Volume: 36 | Issue: 18 | Pages: 1840-1846

10.1200/jco.2017.75.9480 | PMID 29676945 Get It

Purpose Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but existing risk prediction models do not provide accurate individualized estimates of risk in this subset of high-risk women. Here, we used the Mayo benign breast disease cohort to develop and validate a model of BC risk prediction that is specifically for women with AH, which we have designated as AH-BC. Patients and Methods Retrospective cohorts of women age 18 to 85 years with pathologically confirmed benign AH from Rochester, MN, and Nashville, TN, were used for model development and external validation, respectively. Clinical risk factors and histologic features of the tissue biopsy were selected using L1-penalized Cox proportional hazards regression. Identified features were included in a Fine and Gray regression model to estimate BC risk, with death as a competing risk. Model discrimination and calibration were assessed in the model-building set and an external validation set. Results The model-building set consisted of 699 women with AH, 142 of whom developed BC (median follow-up, 8.1 years), and the external validation set consisted of 461 women with 114 later BC events (median follow-up, 11.4 years). The final AH-BC model included three covariates: age at biopsy, age at biopsy squared, and number of foci of AH. At 10 years, the AH-BC model demonstrated good discrimination (0.63 [95% CI, 0.57 to 0.70]) and calibration (0.87 [95% CI, 0.66 to 1.24]). In the external validation set, the model showed acceptable discrimination (0.59 [95% CI, 0.51 to 0.67]) and calibration (0.91 [95% CI, 0.65 to 1.42]). Conclusion We have created a new model with which to refine BC risk prediction for women with AH. The AH-BC model demonstrates good discrimination and calibration, and it validates in an external data set.
Genetic overlap between endometriosis and endometrial cancer: evidence from cross‐disease genetic correlation and GWAS meta‐analyses
Painter, Jodie N. , O’Mara, Tracy A. , Morris, Andrew P. , Cheng, Timothy, Gorman, Maggie, Martin, Lynn , Hodson, Shirley, Henders, Anjali K. , McEvoy, Mark , Holliday, Elizabeth , Scott, Rodney J. , Webb, Penelope M. , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Rübner, Matthias, Dörk, Thilo , Hillemanns, Peter , Runnebaum, Ingo B. , Lambrechts, Diether , Annibali, Daniela , Depreeuw, Jeroen, Goode, Ellen L. , Cunningham, Julie M. , Dowdy, Sean C. , Trovik, Jone , Høivik, Erling A. , Werner, Henrica M.J., Krakstad, Camilla , Ashton, Katie A. , Otton, Geoffrey, Proietto, Tony, Tham, Emma , Mints, Miriam, Healey, Catherine S., Shah, Mitul , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Hopper, John L. , Peto, Julian , Swerdlow, Anthony J. , Burwinkel, Barbara , Brenner, Hermann , Meindl, Alfons, Brauch, Hiltrud , Lindblom, Annika , Chang‐Claude, Jenny , Couch, Fergus J. , Kristensen, Vessela N. , Zondervan, Krina T. , Nyholt, Dale R. , MacGregor, Stuart , Tomlinson, Ian , Easton, Douglas F. , Thompson, Deborah J. , Lambrechts, Diether , Fasching, Peter A , Dörk, Thilo , Lambrechts, Diether , Goode, Ellen L , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , O'Mara, Tracy A , Lambrechts, Diether , Brenner, Hermann , Ekici, Arif B , Michailidou, Kyriaki , MacGregor, Stuart , Jones, Angela , Martin, Nicholas G. , Gordon, Scott D. , Attia, John , Hall, Per N , Czene, Kamila , Dürst, Matthias , Amant, Frédéric , Vanderstichele, Adriaan , Winham, Stacey J. , Mints, Miriam , Ahmed, Shahana , Pharoah, Paul D.P. , Dunning, Alison M. , Dennis, Joe , Tyrer, Jonathan P. , Meindl, Alfons, Couch, Fergus J. , Giles, Graham G. , Cox, Angela , Montgomery, Grant W. , Spurdle, Amanda B. , Brauch, Hiltrud , Lindblom, Annika

Mayo Clinic

Cancer Medicine | April 2, 2018 | Volume: 7 | Issue: 5 | Pages: 1978-1987

10.1002/cam4.1445 | PMID 29608257 Get It

AbstractEpidemiological, biological, and molecular data suggest links between endometriosis and endometrial cancer, with recent epidemiological studies providing evidence for an association between a previous diagnosis of endometriosis and risk of endometrial cancer. We used genetic data as an alternative approach to investigate shared biological etiology of these two diseases. Genetic correlation analysis of summary level statistics from genomewide association studies (GWAS) using LD Score regression revealed moderate but significant genetic correlation (rg = 0.23, P = 9.3 × 10−3), and SNP effect concordance analysis provided evidence for significant SNP pleiotropy (P = 6.0 × 10−3) and concordance in effect direction (P = 2.0 × 10−3) between the two diseases. Cross‐disease GWAS meta‐analysis highlighted 13 distinct loci associated at P ≤ 10−5 with both endometriosis and endometrial cancer, with one locus (SNP rs2475335) located within PTPRD associated at a genomewide significant level (P = 4.9 × 10−8, OR = 1.11, 95% CI = 1.07–1.15). PTPRD acts in the STAT3 pathway, which has been implicated in both endometriosis and endometrial cancer. This study demonstrates the value of cross‐disease genetic analysis to support epidemiological observations and to identify biological pathways of relevance to multiple diseases.
Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer
Natanzon, Yanina , Earp, Madalene A. , Cunningham, Julie M. , Kalli, Kimberly R., Armasu, Sebastian M. , Bowtell, David D.L. , Garsed, Dale W. , Goode, Ellen L. , Earp, Madalene, Bowtell, David D , Wang, Chen , Larson, Melissa C. , Fridley, Brooke L. , Winham, Stacey J. , Garsed, Dale W

Mayo Clinic

Cancer Informatics | February 1, 2018 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/1176935118755341 | PMID 29434467 Get It

High-grade serous ovarian cancer (HGSOC) is a complex disease in which initiation and progression have been associated with copy number alterations, epigenetic processes, and, to a lesser extent, germline variation. We hypothesized that, when summarized at the gene level, tumor methylation and germline genetic variation, alone or in combination, influence tumor gene expression in HGSOC. We used Elastic Net (ENET) penalized regression method to evaluate these associations and adjust for somatic copy number in 3 independent data sets comprising tumors from more than 470 patients. Penalized regression models of germline variation, with or without methylation, did not reveal a role in HGSOC gene expression. However, we observed significant association between regional methylation and expression of 5 genes ( WDPCP, KRT6C, BRCA2, EFCAB13, and ZNF283). CpGs retained in ENET model for BRCA2 and ZNF283 appeared enriched in several regulatory elements, suggesting that regularized regression may provide a novel utility for integrative genomic analysis.
Sex hormones in alcohol consumption: a systematic review of evidence
Erol, Almıla , Ho, Ada Man‐Choi , Winham, Stacey J. , Karpyak, Victor M. , Ho, Ada M-C , Winham, Stacey J , Karpyak, Victor

Mayo Clinic

Addiction Biology | December 27, 2017 | Volume: 24 | Issue: 2 | Pages: 157-169

10.1111/adb.12589 | PMID 29280252 Get It

AbstractSex hormones play an important role in establishing sex‐distinctive brain structural and functional variations that could contribute to the sex differences in alcohol consumption behavior. Here, we systematically reviewed articles that studied sex hormone impacts on alcohol consumption and alcohol use disorder (AUD). An extensive literature search conducted in MEDLINE, PubMed, Scopus and CINAHL databases identified 776 articles, which were then evaluated for pre‐specified criteria for relevance and quality assurance. A total of 50 articles, including 19 human studies and 31 animal studies, were selected for this review. Existing evidence supports the association of increased testosterone level and increased risk for alcohol use and AUD in males but results are inconclusive in females. In contrast, the evidence supports the association of increased estrogen level and increased alcohol use in females, with mixed findings reported in males. Much less is known about the impact of progestins on alcohol use and misuse in human subjects. Future observational and experimental studies conducted in both sexes with a comprehensive hormone panel are needed to elucidate the impact of the interplay between various sex hormone levels during various developmental stages on alcohol use‐related phenotypes and AUD.
Macrophagic “Crown-like Structures” Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease
Carter, Jodi M. , Pena, Monica-Cătălina, Brahmbhatt, Rushin, Frost, Marlene H., Stallings‐Mann, Melody , Knutson, Keith L. , Visscher, Daniel W., Hoskin, Tanya L. , Pena, M Alvaro, Stallings-Mann, Melody, Radisky, Derek C. , Winham, Stacey J. , Knutson, Keith L. , Degnim, Amy C. , Carter, Jodi

Mayo Clinic

Cancer Prevention Research | November 22, 2017 | Volume: 11 | Issue: 2 | Pages: 113-119

10.1158/1940-6207.capr-17-0245 | PMID 29167285 Get It

Abstract In breast adipose tissue, macrophages that encircle damaged adipocytes form “crown-like structures of breast” (CLS-B). Although CLS-B have been associated with breast cancer, their role in benign breast disease (BBD) and early carcinogenesis is not understood. We evaluated breast biopsies from three age-matched groups (n = 86 each, mean age 55 years), including normal tissue donors of the Susan G. Komen for the Cure Tissue Bank (KTB), and subjects in the Mayo Clinic Benign Breast Disease Cohort who developed cancer (BBD cases) or did not develop cancer (BBD controls, median follow-up 14 years). Biopsies were classified into histologic categories, and CD68-immunostained tissue sections were evaluated for the frequency and density of CLS-B. Our data demonstrate that CLS-B are associated with BBD: CLS-B–positive samples were significantly less frequent among KTB biopsies (3/86, 3.5%) than BBD controls (16/86 = 18.6%, P = 0.01) and BBD cases (21/86 = 24%, P = 0.002). CLS-B were strongly associated with body mass index (BMI); BMI < 25: 7% CLS-B positive, BMI 25–29: 13%, and BMI ≥ 30: 29% (P = 0.0005). Among BBD biopsies, a high CLS-B count [>5 CLS-B/sample: 10.5% (BBD cases) vs 4.7% (BBD controls), P = 0.007] conferred a breast cancer OR of 6.8 (95% CI, 1.4–32.4), P = 0.02, after adjusting for adipose tissue area (cm2), histologic impression, and BMI. As high CLS-B densities are independently associated with an increased breast cancer risk, they may be a promising histologic marker of breast cancer risk in BBD. Cancer Prev Res; 11(2); 113–9. ©2017 AACR.
An integrative approach to assess X‐chromosome inactivation using allele‐specific expression with applications to epithelial ovarian cancer
Larson, Nicholas B. , Fogarty, Zachary C. , Kalli, Kimberly R., Lawrenson, Kate , Gayther, Simon A. , Goode, Ellen L. , Winham, Stacey J. , Winham, Stacey J , Lawrenson, Kate , Fogarty, Zachary C , Larson, Nicholas B , Larson, Melissa C. , Fridley, Brooke L.

Mayo Clinic

Genetic Epidemiology | November 9, 2017 | Volume: 41 | Issue: 8 | Pages: 898-914

10.1002/gepi.22091 | PMID 29119601 Get It

ABSTRACTX‐chromosome inactivation (XCI) epigenetically silences transcription of an X chromosome in females; patterns of XCI are thought to be aberrant in women's cancers, but are understudied due to statistical challenges. We develop a two‐stage statistical framework to assess skewed XCI and evaluate gene‐level patterns of XCI for an individual sample by integration of RNA sequence, copy number alteration, and genotype data. Our method relies on allele‐specific expression (ASE) to directly measure XCI and does not rely on male samples or paired normal tissue for comparison. We model ASE using a two‐component mixture of beta distributions, allowing estimation for a given sample of the degree of skewness (based on a composite likelihood ratio test) and the posterior probability that a given gene escapes XCI (using a Bayesian beta‐binomial mixture model). To illustrate the utility of our approach, we applied these methods to data from tumors of ovarian cancer patients. Among 99 patients, 45 tumors were informative for analysis and showed evidence of XCI skewed toward a particular parental chromosome. For 397 X‐linked genes, we observed tumor XCI patterns largely consistent with previously identified consensus states based on multiple normal tissue types. However, 37 genes differed in XCI state between ovarian tumors and the consensus state; 17 genes aberrantly escaped XCI in ovarian tumors (including many oncogenes), whereas 20 genes were unexpectedly inactivated in ovarian tumors (including many tumor suppressor genes). These results provide evidence of the importance of XCI in ovarian cancer and demonstrate the utility of our two‐stage analysis.
Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Goode, Ellen L. , Block, Matthew S. , Kalli, Kimberly R., Vierkant, Robert A. , Fogarty, Zachary C. , Tołoczko, Aleksandra, Hein, Alexander , Bouligny, Aliecia L., Jensen, Allan , Osório, Ana , Ryan, Andy , Magliocco, Anthony M., Hartmann, Arndt , Gao, Bo , McCauley, Bryan M. , Kennedy, Catherine J. , Karpinskyj, Chloe , Sousa, Christiani Bisinoto de, Tiezzi, Daniel Guimarães , Wachter, David L., Herpel, Esther , Taran, Florin‐Andrei , Nelson, Gregg , Menkiszak, Janusz , Alsop, Jennifer , Lester, Jenny , García-Donás, Jesús , Nation, Jill, Hung, Jillian A., Palacios, José , Rothstein, Joseph H. , Kelley, Joseph L., Andrade, Jurandyr Moreira de , Robles-Díaz, Luis, Intermaggio, Maria P., Widschwendter, Martin , Beckmann, Matthias W. , Ruebner, Matthias , Jimenez‐Liñan, Mercedes , Singh, Naveena , Oszurek, Oleg, Harnett, Paul R. , Rambau, Peter , Sinn, Hans‐Peter , Wagner, Philipp , Sharma, Raghwa , Ness, Roberta B., Oršulić, Sandra , Johnatty, Sharon E., Longacre, Teri A. , Eilber, Ursula, McGuire, Valerie , Sieh, Weiva , Natanzon, Yanina , Li, Zheng , Whittemore, Alice S. , DeFazio, Anna , Staebler, Annette , Bowtell, David D.L. , Høgdall, Estrid , Reis, Francisco José Cândido dos , Steed, Helen , Campbell, Ian , Benı́tez, Javier , Koziak, Jennifer M. , Chang‐Claude, Jenny, Moysich, Kirsten B. , Kelemen, Linda E. , Goodman, Marc T. , García, María J. , Fasching, Peter A. , Kommoss, Stefan , Deen, Suha , Menon, Usha , Chenevix‐Trench, Georgia , Huntsman, David G. , Köbel, Martin , Ramus, Susan J. , Winham, Stacey J. , Fazio, Anna de , Ramus, Susan J , Köbel, Martin , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Campbell, Ian G , García-Donas, Jesús , Kennedy, Catherine J , Menkiszak, Janusz , Sinn, Peter , Widschwendter, Martin , Fogarty, Zachary C , Sieh, Weiva , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Estrid , Bowtell, David D , Chen, Wenqian , Gentry‐Maharaj, Aleksandra , Bouligny, Aliecia, Hartkopf, Andreas D , Chudecka-Glaz, Anita Monika , Jung, Audrey , Hernandez, Brenda Y. , Fridley, Brooke L. , Wang, Chen , Modugno, Francesmary , Lubiński, Jan , Robles-Díaz, Luis, Ghatage, Prafull , Edwards, Todd , Brucker, Sara Yvonne , Karlan, Beth Y. , Gilks, C. Blake , Gronwald, Jacek , Cook, Linda S. , Kjær, Susanne K. , Brenton, James D. , Pharoah, Paul D.P. , Nelson, Gregg S , Harnett, Paul R , Steed, Helen , Goodman, Marc T

Mayo Clinic

JAMA Oncology | October 19, 2017 | Volume: 3 | Issue: 12 | Pages: e173290

10.1001/jamaoncol.2017.3290 | PMID 29049607 Get It

Abstract 5299: Validation of the BCSC model within the Mayo Benign Breast Disease Cohort
Frank, Ryan D. , Vachon, Celine M. , Frost, Marlene H., Visscher, Daniel W., Vachon, Celine M. , Winham, Stacey J. , Vierkant, Robert A. , Radisky, Derek C. , Degnim, Amy C.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 5299-5299

10.1158/1538-7445.am2017-5299 Get It

Abstract Background: The Breast Cancer Surveillance Consortium (BCSC) model predicts invasive breast cancer risk in women with Benign Breast Disease (BBD), and recently incorporated BBD histology into the model. The BCSC has been validated in the Mayo Mammography Health Study, but has yet to be examined in Mayo Clinic’s BBD cohort. The Benign Breast Disease to Breast Cancer (BBD-BC) model predicts risk of both invasive and in situ breast cancer. Here we compare the performance of the BCSC and BBD-BC in Mayo Clinic’s BBD cohort. Methods: Eligible women underwent a breast biopsy with benign findings at the Mayo Clinic between years 1997-2001 and had a 4-view screening mammogram within six months of biopsy. Clinical BI-RADS density assessments using the 4th edition American College of Radiology were available on all mammograms, and were coded as almost entirely fat, scattered fibroglandular densities, heterogeneously dense, and extremely dense. Risk at 5 and 10 years of invasive cancer only (BCSC model) or both invasive and in situ cancer (BBD-BC model) were estimated. In situ cancers were censored at time of diagnosis for both models. Concordance statistics, i.e. model discrimination (higher is better), for each model were calculated using a Cox proportional hazards model with predicted risk as the sole predictor, and were compared using permutation tests. The ratio of total predicted (sum of predicted risk) to observed number of invasive breast cancers was used to assess model calibration. Calibration was not formally compared across models due to differences in how DCIS was treated in the development of each (BCSC censored; BBD-BC event). Results: 999 women met inclusion criteria. BI-RADS density was categorized as fatty in 46 (4.6%), scattered densities in 372 (37.2%), heterogeneously dense in 423 (42.3%), and extremely dense in 158 (15.8%). 62 invasive cancers occurred over a median 13.3yrs of follow-up, with 16 (25.8%) and 48 (77.4%) of the cancers occurring with-in 5 and 10 years. The concordance of the BCSC at 5 years was 0.550 (95% CI 0.409—0.691), compared to 0.719 (95% CI 0.578—0.860) for the BBD-BC (p-value=0.005). At 10 years the BCSC concordance was not significantly different from the BBD-BC, at 0.624 (95% CI 0.542—0.706) and 0.662 (95% CI 0.580—0.744), respectively (p-value=0.306). The BCSC over predicted the number invasive cancers in the BBD cohort at 5 years (predicted-to-observed=1.54; 95% CI 1.01—2.70), but was well calibrated at 10 years (1.06; 95% CI 0.83, 1.47). Conclusions: The BCSC model performed reasonably well in the BBD Cohort 10 years post-biopsy, but overestimated risk at 5 years. Additional study is needed to improve models for prediction of breast cancer risk among women with BBD. Citation Format: Ryan D. Frank, Celine M. Vachon, Stacey J. Winham, Robert A. Vierkant, Marlene H. Frost, Derek C. Radisky, Daniel W. Visscher, Amy C. Degnim. Validation of the BCSC model within the Mayo Benign Breast Disease Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5299. doi:10.1158/1538-7445.AM2017-5299
Abstract 3368: Omics data integration analysis in high grade serous ovarian cancer: results from three studies
Natanzon, Yanina , Earp, Madalene A. , Cunningham, Julie M. , Kalli, Kimberly R., Armasu, Sebastian M. , Wang, Chen , Garsed, Dale W. , Goode, Ellen L. , Winham, Stacey J. , Larson, Melissa C. , Bowtell, David D.L. , Garsed, Dale W

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 3368-3368

10.1158/1538-7445.am2017-3368 Get It

Abstract High grade serous ovarian cancer (HGSOC) is a complex disease in which initiation and progression have been associated with gene mutation, DNA methylation changes, genetic variation, and epigenetic processes. Variation in several susceptibility regions and cancer-typical global methylation patterns have been observed in HGSOC; however, this knowledge has not been compelling in understanding HGSOC intiation or progression. As ingetration of genomic, epigenomic, and transcriptomic data has increased mechanistic understanding in other cancers, we hypothesized that tumor methylation alone or in combination with germline genetic variation influences tumor gene expression in HGSOC. We examined three nested models using an Elastnic Net (ENET) penalized regression method while adjusting for somatic copy number (CNV): a) germline genotype and tumor DNA methylation (full model), b) genotype only, and c) DNA methylation only. We included 339 cases from The Cancer Genome Atlas (TCGA), 54 cases from Mayo Clinic, and 78 cases from the Australian Ovarian Cancer Study (AOCS). Genotyping and copy number calls on germline DNA, expression, methylation and copy number on somatic samples were collected and analyzed on different platforms separately at each study site. We excluded genes with low overall expression and thus analyzed a total of 11,922 genes available in three datasets ( Ensembl IDs, 500kb window up- and downstream). In general, combining genomic data in HGSOC did not reveal a role for germline genetic variation in altering gene expression. However, in methylation only models 79 genes were associated with differential expression in the TCGA cases (permutation multiple testing adjusted p-val <0.05), in the Mayo cases (unadjusted p-val <0.05) and AOCS cases (unadjusted p-val <0.05). A known tummor suppressor (FBXW7) was associated with differential expression in the three datasets at p-val <0.01. This work demonstrates the feasibility, utility, and statistical power of ENET gene-level analyses incoporating maximal genomic information. Citation Format: Yanina Natanzon, Madalene Earp, Julie M. Cunningham, Kimberly R. Kalli, Stacey J. Winham, Sebastian M. Armasu, Melissa C. Larson, Chen Wang, David D. Bowtell, Dale W. Garsed, Ellen Goode. Omics data integration analysis in high grade serous ovarian cancer: results from three studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3368. doi:10.1158/1538-7445.AM2017-3368